Allogene Therapeutics, Inc.
NASDAQ:ALLOBiotechnology
+$0.02 today
- Market cap
- $241.11M
- Beta
- 0.46
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.72
Volume 10.55M
Average 10.19M
ALLO Total Liabilities
Everything the company owes to creditors and other parties.
Allogene Therapeutics, Inc.NASDAQ: ALLO
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 4.5% from a year ago
Total liabilities stood at $117.08M at the end of Q1 FY2026, down 4.5% from a year earlier and down 5.1% from the prior quarter. Over 3 fiscal years it compounded at -7.3% a year.
Context
- Total liabilities amounted to 29.6% of total assets at the end of Q1 FY2026, up 5.4 pp from a year earlier.
- Total liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -4.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 123.36M USD
- Year-over-year change
- -2.5%
- 4-year CAGR
- -0.5%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 123.36M | -2.5% |
| FY2024 | 2024-12-31 | 126.53M | -3.1% |
| FY2023 | 2023-12-31 | 130.6M | -15.6% |
| FY2022 | 2022-12-31 | 154.7M | +23.1% |
| FY2021 | 2021-12-31 | 125.63M | — |
Total Liabilities vs competitors
How ALLO compares with its peers on the latest reported figures
- ALLO's Mar 2026 total liabilities of $117.08M is the 4th highest of the 9 companies compared; the peer median is $86.5M.
- Its year-over-year change of -4.5% is the 3rd highest of 9, against a peer median of -8.6%.
- Total liabilities amounts to 29.6% of total assets for ALLO, versus a peer median of 63.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $418.24M | +11.5% | +29.0% | 79.4% | |
| Mar 2026 | $229.27M | -7.5% | +22.5% | 79.3% | |
| Dec 2025 | $145.39M | +17.4% | -10.4% | 135.5% | |
| Mar 2026 | $117.08M | -4.5% | -7.3% | 29.6% | |
| Mar 2026 | $105.21M | -4.6% | -20.4% | 36.9% | |
| Mar 2026 | $67.79M | -9.7% | -29.5% | 47.1% | |
| Mar 2026 | $61.81M | -17.8% | -29.4% | 18.9% | |
| Mar 2026 | $57.31M | -51.1% | -38.3% | 286.6% | |
| Mar 2026 | $46.98M | -16.8% | -10.0% | 31.5% | |
| Peer median (excluding ALLO) | $86.5M | -8.6% | -15.4% | 63.2% | |
Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 173.31M | 61.9M | 83.16M | 75.22M | 51.69M |
| Short-term Investments | 283.99M | 455.42M | 365.54M | 217.26M | 198.52M |
| Net Receivables | 0 | 0 | 1.7M | 1.9M | 1.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 11.5M | 0 | 9.01M | 6.04M |
| Total Current Assets | 471.32M | 528.82M | 459.12M | 303.39M | 257.75M |
| Property, Plant & Equipment (Net) | 181.02M | 196.43M | 163.18M | 131.26M | 112.73M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 382.38M | 76.47M | 3.65M | 80.67M | 8.04M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 16.11M | 19.86M | 16.9M | 33.39M | 37.39M |
| Total Non-current Assets | 579.51M | 292.76M | 183.72M | 245.32M | 158.16M |
| Total Assets | 1.05B | 821.58M | 642.84M | 548.71M | 415.91M |
| Account Payables | 10.26M | 13.89M | 5.9M | 5.39M | 4.27M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 156K | 95K | 86K | 0 | 0 |
| Other Current Liabilities | 16.13M | 17.94M | 11.66M | 12.15M | 10.24M |
| Total Current Liabilities | 47.91M | 53.73M | 37.08M | 35.52M | 32.51M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.79M | 5.85M | 5.18M | 7.76M | 15.8M |
| Total Non-current Liabilities | 77.72M | 100.97M | 93.53M | 91.01M | 90.85M |
| Total Liabilities | 125.63M | 154.7M | 130.6M | 126.53M | 123.36M |
| Common Stock | 142K | 144K | 169K | 212K | 229K |
| Retained Earnings | (894.55M) | (1.23B) | (1.56B) | (1.82B) | (2.01B) |
| Accumulated OCI | (2.57M) | (9.93M) | (955K) | (89K) | 269K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 925.2M | 666.88M | 512.23M | 422.18M | 292.54M |
| Total Debt | 73.13M | 101.12M | 95.12M | 90.76M | 83.25M |
| Net Debt | (100.19M) | 39.22M | 11.97M | 15.54M | 31.57M |
Allogene Therapeutics, Inc.
NASDAQ:ALLO
Intrinsic Alpha fair value
Locked
Current Price
$0.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.